Kintara Therapeutics Overview
Get informed when a big investor buys or sells
+ Follow-2.78
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Kintara Therapeutics (KTRA) currently reports a P/E ratio of -2.78. That is below the Materials sector average of 18.08. Use the charts on this page to explore Kintara Therapeutics's P/E ratio history and peer comparisons.
Kintara Therapeutics's P/E ratio of -2.78 is lower than the Materials sector average of 18.08. That is roughly 115.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Kintara Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -2.78, KTRA can look expensive or cheap only in context — versus its own history, growth rate, and Materials peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -2.78, then check the historical chart for trend and the peer comparison chart for relative positioning. The Materials average is 18.08. From there, open related valuation or income-statement pages for Kintara Therapeutics, and consider following KTRA for alerts when major investors trade the stock.
Kintara Therapeutics is classified in the Materials sector. On P/E ratio, it currently shows -2.78 versus a sector average near 18.08. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Materials are usually more informative than comparing KTRA with unrelated industries.
